公司资料
Arcutis Biotherapeutics 股价、新闻与催化剂
- 股票代码:
- ARQT
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
25.61 USD (-2.21%)
收盘价
最后更新: 2026年8月17日
2.6B USD
市值
股价为何变动
As of Aug 17, 2026, ARQT closed down 2.21% at $25.61. No new same-company headline was identified in the current news window.
公司概览
Medical Dermatology
Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology.
ZORYVE Franchise
ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic dermatitis and seborrheic dermatitis.
Pediatric Expansion
Arcutis is seeking to extend ZORYVE cream to infants with atopic dermatitis and ZORYVE foam to younger children with scalp and body plaque psoriasis.
New ZORYVE Indications
Phase 2 proof-of-concept studies are evaluating ZORYVE foam in vitiligo and hidradenitis suppurativa.
ARQ-234
ARQ-234 is a biologic candidate in initial clinical development for moderate-to-severe atopic dermatitis, expanding Arcutis beyond topical PDE4 inhibition.
未来催化剂
- FDA review milestones for the ZORYVE cream infant-atopic-dermatitis sNDA.
- Phase 2 vitiligo results and an advancement decision in the fourth quarter of 2026.
- Phase 2 hidradenitis-suppurativa results and an advancement decision in the first quarter of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。